Exenatide trumps insulin glargine in cost effectiveness

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.586, 2009-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Exenatide is associated with significantly lower medical costs than insulin glargine

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 594, 2010-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Modelling Cost Effectiveness of Insulin Glargine for the Treatment of Type 1 and 2 Diabetes in Canada

By Grima Daniel T.

PharmacoEconomics, Vol. 25, Iss. 3, 2007-01 ,pp. : 253-266

Adis International

Access to resources Recommend Favorite

Insulin Glargine

By Gillies P.S. Figgitt D.P. Lamb H.M.

Drugs, Vol. 59, Iss. 2, 2000-02 ,pp. : 253-260

Adis International

Access to resources Recommend Favorite

Insulin glargine: timing not an issue

Inpharma, Vol. 1, Iss. 1397, 2003-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Insulin glargine dually compared

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 591, 2009-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite